This unregistered trial (n=10) was a quality-improvement pilot of ketamine-assisted group therapy for mental health in an Indigenous cohort, which reported significant perceived benefits and highlighted the importance of cultural safety.
This synthetic trial has been added to our database because a psychedelic paper (about a clinical trial) references this trial, but no (live) registration can be found.
The study was a community-based quality-improvement pilot conducted in partnership with the Snuneymuxw First Nation. The intervention consisted of a 12-week programme involving weekly two-hour virtual sessions and three in-person group ketamine sessions administered intramuscularly at doses of 1.0–1.5 mg/kg. Participants also received virtual integration sessions following the ketamine administrations.
The cohort included eight participants in a discrete Indigenous small group and two Elders in mixed groups. Qualitative analysis of interviews and feedback indicated that participants experienced significant benefits, though the study emphasised the necessity of involving Indigenous team members and incorporating traditional healing approaches to ensure cultural safety and effective reconciliation within psychedelic medicine.
A 12-week program including weekly 2-hour virtual sessions and three in-person group ketamine sessions.
Dose range 1.0-1.5 mg/kg administered intramuscularly during in-person group sessions at weeks four, six, and eight.